Loading…
Theravance Biopharma, Inc. is projected to rise to $20.31 by 2027, a +20% move from its current price of $16.86. TBPH is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 8/1/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Aug 2 | $16.71 | $16.86 | $17.02 | +0.03% |
| Aug 3 | $16.65 | $16.87 | $17.09 | +0.06% |
| Aug 4 | $16.60 | $16.87 | $17.15 | +0.08% |
| Aug 5 | $16.57 | $16.88 | $17.20 | +0.11% |
| Aug 6 | $16.53 | $16.88 | $17.24 | +0.14% |
| Aug 7 | $16.50 | $16.89 | $17.28 | +0.17% |
| Aug 8 | $16.48 | $16.89 | $17.32 | +0.20% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $16.48 | $16.89 | $17.32 | +0.20% |
| Week 2 | $16.34 | $16.93 | $17.53 | +0.39% |
| Week 3 | $16.25 | $16.96 | $17.70 | +0.59% |
| Week 4 | $16.17 | $16.99 | $17.86 | +0.79% |
| Week 5 | $16.11 | $17.03 | $18.00 | +0.99% |
| Week 6 | $16.05 | $17.06 | $18.13 | +1.19% |
| Week 7 | $16.01 | $17.09 | $18.25 | +1.39% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Theravance Biopharma, Inc. is a healthcare company that develops and commercializes medicines in the United States.
Its product offerings include YUPELRI, an once-daily, nebulized long-acting muscarinic antagonist for the treatment of COPD, and Ampreloxetine, an investigational, once-daily norepinephrine reuptake inhibitor that is in Phase 3 clinical trials for symptomatic neurogenic orthostatic hypotension (nOH) in patients with Multiple System Atrophy (MSA).
The company has a strategic collaboration agreement with Viatris Inc. for the development and commercialization of revefenacin, including YUPELRI inhalation solution. Theravance Biopharma, Inc. was incorporated in 2013 and is based in South San Francisco, California.
Theravance Biopharma, Inc. (TBPH) operates in the Healthcare space as a biopharmaceutical company focused on developing and commercializing medicines in the United States.
The stock is currently priced at $16.81 and carries a market capitalization of $871.23M, with a rank of 2536.
The forward-looking forecast shows upside potential over the long run. The 2026 average price is $16.81 (the current price), and the trajectory proceeds toward higher targets through 2050, with the 2027 average at $20.84 and the 2050 average at $270.37, reflecting a bullish tilt starting in 2027.
A major floor 11.6% below — a decisive break under it would weaken the trend.
Price is testing support right now (1.8% away) — a key level to hold.
The nearest ceiling, 4.6% above — a clean break opens room to run.
A major ceiling 7.3% above — clearing it would confirm fresh momentum.
Key TBPH support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of TBPH market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $16.86 | Sell | $16.86 | Buy |
| MA 10 | $16.85 | Buy | $16.87 | Sell |
| MA 20 | $16.90 | Sell | $16.87 | Sell |
| MA 50 | $16.69 | Buy | $16.78 | Buy |
| MA 100 | $16.31 | Buy | $16.71 | Buy |
| MA 200 | $17.05 | Sell | $16.15 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 50.50 | Neutral |
| Stoch RSI (14) | 33.17 | Neutral |
| CCI (20) | -52.79 | Neutral |
| Williams %R (14) | -68.75 | Info |
| MACD (12,26,9) | -0.02 | Sell |
| ROC (12) | -0.41 | Sell |
| Bollinger %B (20,2) | 0.33 | Neutral |
| Stochastic %K (14) | 31.25 | Neutral |
| TRIX (15) | 0.04 | Buy |
| Awesome (5,34) | -0.04 | Sell |
| Ultimate (7,14,28) | 60.53 | Neutral |
| Momentum (10) | -0.07 | Sell |
| Aroon Osc (25) | -68.00 | Sell |
| Hull MA (9) | 16.86 | Sell |
| ADX (14) | 5.84 | Neutral |
| ATR (14) | 0.06 | Info |
The 30-day technical picture is Neutral, with an RSI of 50. The 50-day moving average stands at $16.63 and the 200-day moving average at $16.96, indicating a tight range around the current level.
Key support is at $16.32 and resistance at $17.63. The 30-day price range spans $15.79 to $17.89, and the stock exhibits about 20% annualized volatility.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $13.57 | $16.86 | $22.42 | 0% | Neutral | |
| $16.65 | $20.31 | $25.88 | +20% | Bullish | |
| $20.12 | $25.01 | $32.74 | +48% | Bullish | |
| $25.27 | $31.89 | $42.65 | +89% | Bullish | |
| $28.23 | $36.12 | $49.19 | +114% | Bullish | |
| $32.97 | $42.70 | $59.07 | +153% | Bullish | |
| $34.69 | $45.43 | $63.76 | +169% | Bullish | |
| $35.25 | $46.66 | $66.33 | +177% | Bullish | |
| $41.91 | $56.03 | $80.60 | +232% | Bullish | |
| $48.49 | $65.43 | $95.18 | +288% | Bullish | |
| $70.04 | $98.58 | $150.30 | +485% | Bullish | |
| $157.02 | $237.04 | $387.46 | +13.1x | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| August 2026 | $13.57 | $16.86 | $20.48 | +0.00% |
| September 2026 | $14.59 | $17.10 | $20.51 | +1.43% |
| October 2026 | $14.68 | $17.30 | $20.90 | +1.15% |
| November 2026 | $15.25 | $18.03 | $21.91 | +4.23% |
| December 2026 | $15.47 | $18.35 | $22.42 | +1.78% |
Click any year to see its month-by-month TBPH forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
In 2026, TBPH is projected to trade between $13.57 and $22.42, averaging $16.86 — a potential gain of 0% from today's $16.86. A consolidation phase looks the most probable path here.
Theravance Biopharma, Inc.'s 2027 outlook centres on $20.31, within a $16.65 to $25.88 range. That is up +20% on the projected 2026 average. That marks a +20% change versus current levels. Momentum favours further upside here.
By 2028, TBPH could reach as high as $32.74, with a base case around $25.01 and support toward $20.12 — roughly +48% from $16.86. Buyers look set to stay in control over this stretch.
Expect TBPH to range from $25.27 to $42.65 through 2029. The $31.89 average target implies a +89% move from current prices. That is up +28% on the projected 2028 average. Momentum favours further upside here.
The TBPH price prediction for 2030 points to an average of $36.12 (low $28.23, high $49.19) — a potential gain of +114% on today's $16.86. Buyers look set to stay in control over this stretch.
In 2031, TBPH is projected to trade between $32.97 and $59.07, averaging $42.70 — a potential gain of +153% from today's $16.86. That is up +18% on the projected 2030 average. Momentum favours further upside here.
Theravance Biopharma, Inc.'s 2032 outlook centres on $45.43, within a $34.69 to $63.76 range. That is up +6% on the projected 2031 average. That marks a +169% change versus current levels. Buyers look set to stay in control over this stretch.
By 2033, TBPH could reach as high as $66.33, with a base case around $46.66 and support toward $35.25 — roughly +177% from $16.86. Momentum favours further upside here.
Expect TBPH to range from $41.91 to $80.60 through 2034. The $56.03 average target implies a +232% move from current prices. That is up +20% on the projected 2033 average. Buyers look set to stay in control over this stretch.
The TBPH price prediction for 2035 points to an average of $65.43 (low $48.49, high $95.18) — a potential gain of +288% on today's $16.86. Momentum favours further upside here.
In 2040, TBPH is projected to trade between $70.04 and $150.30, averaging $98.58 — a potential gain of +485% from today's $16.86. That is up +51% on the projected 2035 average. Buyers look set to stay in control over this stretch.
Theravance Biopharma, Inc.'s 2050 outlook centres on $237.04, within a $157.02 to $387.46 range. That is up +140% on the projected 2040 average. That marks a +13.1x change versus current levels. Momentum favours further upside here.
Investing $1,000 in TBPH today (≈ 59.311981 TBPH) could be worth
$14,059.56
+$13,059.56 (+1306%) by 2050 · US Dollar
Based on the average projected TBPH price of $237.04 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in TBPHwould be worth at today's price.
$1,000 invested in TBPH on Jul 31, 2025 (≈ 89.605736 TBPH) would be worth
$1,510.75
+$510.75 (+51.1%) today · 1.51× · US Dollar
Based on a TBPH entry price of $11.16 vs. today's $16.86.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $16.86 | $1,000 | -0.0% |
| 1 month ago | $16.98 | $992.93 | -0.7% |
| 3 months ago | $16.79 | $1,004.17 | +0.4% |
| 6 months ago | $19.83 | $850.23 | -15.0% |
| 1 year ago | $11.16 | $1,510.75 | +51.1% |
| All time (5.0y) ago | $13.82 | $1,219.97 | +22.0% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our TBPH forecast.
Our base-case forecast reaches $34.00 around 2030.
Implied market cap at $34.00: $1.76B
The multi-year forecast shows a bullish trajectory beginning in 2027, with the 2027 average price at $20.84 and the 2028 average at $26.09, followed by a 2030 average of $38.41. The projections continue to rise, reaching a 2035 average of $72.02 and a 2040 average of $111.31, with a 2050 average of $270.37.
ROI figures rise from 24% in 2027 to 128.5% in 2030, then progress to 328.4% in 2035, 562.1% in 2040, and 1508.4% in 2050, with sentiment turning bullish from 2027 onward.
These are estimates and not guarantees, and actual results depend on market conditions and company developments.
Tap a question to reveal the answer.
Avg price $38.41, min $30.01, max $52.33; ROI 128.5%; sentiment BULLISH.
Forecasts show bullish sentiment from 2027 onward, with 2027 avg $20.84 and 2028 avg $26.09, and long-run upside (2030 avg $38.41; 2040 avg $111.31; 2050 avg $270.37). The ROIs rise to 128.5% by 2030 and beyond.
Yes, the max forecast price by 2035 is $104.79.
Current price $16.81; market cap $871.23M.
Sentiment NEUTRAL; RSI 50; SMA50 $16.63; SMA200 $16.96; support $16.32; resistance $17.63; 30-day range $15.79-$17.89; annualized volatility 20%.
Theravance Biopharma, Inc. Community Discussion
0Share your Theravance Biopharma, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.